论文部分内容阅读
目的:探讨甲状腺自身抗体阳性甲亢病的131I治疗与甲减关系。方法:将2010年7月到2010年10月于我院核医学科诊断甲亢病且采用131I治疗的271例患者,根据甲状腺自身抗体分为甲亢病伴甲状腺自身抗体阳性组(实验组)152例,甲亢病伴甲状腺自身抗体阴性组(对照组)119例,比较两组疗效。结果:甲状腺自身抗体阳性患者治疗后甲减发生明显增高。结论:131I治疗甲亢时,对甲状腺自身抗体阳性患者要减少用药量,同时应常规查甲状腺自身抗体,以减少早发甲减的发生。
Objective: To investigate the relationship between thyroid autoantibody-positive hyperthyroidism (131I) and hypothyroidism (Hypothyroidism). Methods: From July 2010 to October 2010 in our hospital nuclear medicine diagnosis of hyperthyroidism and 131I treatment of 271 patients, according to thyroid autoantibodies were divided into hyperthyroidism with thyroid autoantibody positive group (experimental group) 152 cases , Hyperthyroidism with thyroid autoantibodies negative group (control group) 119 cases, the efficacy of the two groups were compared. Results: Thyroid autoantibody positive patients after treatment, hypothyroidism was significantly higher. Conclusion: 131I treatment of hyperthyroidism, thyroid autoantibody-positive patients to reduce the dosage, thyroid autoantibodies should be routinely checked to reduce the incidence of early hypothyroidism.